Theriva Biologics, Inc. (TOVX) Stock Price

TOVXStock

$0.24−45.13%52W

Market Cap$10.90M

P/E—

PEG Ratio—

Div yield—

Beta1.19

TOVX Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)11.20%

Price vs S&P 500 (4W)7.07%

VGM Score41.49

Book Value / Share (Quarterly)$0.34

P/TBV (Annual)2.85x

Cash Flow / Share (Quarterly)$-0.31

Price vs S&P 500 (YTD)-0.22%

Gross Margin (TTM)71.52%

Net Profit Margin (TTM)-681.33%

EPS (TTM)$-2.50

10-Day Avg Trading Volume0.59M

EPS Excl Extra (TTM)$-2.50

EPS (Annual)$-1.96

ROI (Annual)-138.74%

Gross Margin (Annual)-20.00%

Net Profit Margin (5Y Avg)-18442.92%

Cash / Share (Quarterly)$0.31

ROA (Last FY)-62.08%

EBITD / Share (TTM)$-1.00

ROE (5Y Avg)-78.60%

Operating Margin (TTM)-709.00%

Cash Flow / Share (Annual)$-0.47

P/B Ratio0.69x

P/B Ratio (Quarterly)0.58x

Net Income / Employee (Annual)$-1,582,600

Net Interest Coverage (TTM)-32.17x

ROA (TTM)-59.96%

EPS Incl Extra (Annual)$-1.96

Current Ratio (Annual)1.74x

Quick Ratio (Quarterly)1.58x

3-Month Avg Trading Volume14.52M

52-Week Price Return-45.13%

Revenue / Employee (TTM)$20,000

Tangible BV / Share (Quarterly)$0.61

P/S Ratio (Annual)4.04x

Asset Turnover (Annual)0.64x

52-Week High$0.86

Operating Margin (5Y Avg)-17385.37%

EPS Excl Extra (Annual)$-1.96

CapEx CAGR (5Y)28.47%

Tangible BV CAGR (5Y)35.96%

26-Week Price Return22.45%

Quick Ratio (Annual)1.64x

13-Week Price Return-20.73%

Total Debt / Equity (Annual)0.11x

Current Ratio (Quarterly)1.63x

Enterprise Value$-2.21M

Asset Turnover (TTM)0.01x

Book Value / Share Growth (5Y)-33.97%

Revenue / Employee (Annual)$0

Pretax Margin (Annual)-45.98%

Cash / Share (Annual)$0.37

3-Month Return Std Dev78.62%

Net Income / Employee (TTM)$-1,430,600

ROE (Last FY)-154.32%

Net Interest Coverage (Annual)-212.50x

EPS Basic Excl Extra (Annual)$-1.96

Receivables Turnover (TTM)17.08x

Total Debt / Equity (Quarterly)0.11x

EPS Incl Extra (TTM)$-2.50

Receivables Turnover (Annual)0.00x

ROI (TTM)-156.24%

P/S Ratio (TTM)35.18x

Pretax Margin (5Y Avg)-18439.01%

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$0.61

Price vs S&P 500 (52W)-63.44%

Year-to-Date Return11.74%

5-Day Price Return4.26%

EPS Normalized (Annual)$-1.96

ROA (5Y Avg)-43.11%

Net Profit Margin (Annual)-65.52%

Month-to-Date Return11.95%

Cash Flow / Share (TTM)$-1.16

EBITD / Share (Annual)$-1.97

Operating Margin (Annual)-45.98%

LT Debt / Equity (Annual)0.11x

ROI (5Y Avg)-75.18%

LT Debt / Equity (Quarterly)0.11x

EPS Basic Excl Extra (TTM)$-2.50

P/TBV (Quarterly)2.85x

P/B Ratio (Annual)0.46x

Pretax Margin (TTM)-681.33%

Book Value / Share (Annual)$0.43

Price vs S&P 500 (13W)-23.53%

Beta1.19x

Revenue / Share (TTM)$0.01

ROE (TTM)-178.29%

52-Week Low$0.16

mGradeC

vgmGradeC

TOVX Earnings Surprise History

Q2 25-1.93est. -0.47

Q3 25-0.45est. -0.38

Q1 26-0.05est. -0.05

TOVX Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.13

Industry Peers — Pharmaceuticals(571)

Symbol	Value Score	Growth Score	Momentum Score	Price
TOVXTheriva Biologics, Inc.	—	—	C	$0.24
LLYEli Lilly & Co.	D	B	B	$1233.66
JNJJohnson & Johnson	D	C	B	$273.14
ABBVABBVIE INC.	D	C	B	$265.79
MRKMerck & Co., Inc.	D	C	A	$156.45
NVSNovartis AG	C	C	C	$159.98
AZNAstraZeneca PLC	C	B	C	$169.66
NVONovo-Nordisk A/S	B	C	C	$48.66
ABTAbbott Laboratories	C	C	B	$116.13
PFEPfizer Inc.	C	D	C	$28.57
VRTXVertex Pharmaceuticals Inc	D	C	B	$552.85
BMYBristol-Myers Squibb Co.	B	B	B	$67.92
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$46.02
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$52.07
REGNRegeneron Pharmaceuticals Inc	C	C	B	$833.56
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	C	$18.35
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$38.10
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	C	$376.37
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$62.07
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$240.08
ZTSZOETIS INC.	B	C	D	$77.29
INSMInsmed, Inc.	F	A	C	$123.89
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$36.47
UTHRUnited Therapeutics Corp	C	C	C	$518.53
GMABGenmab A/S ADS	C	C	B	$34.36
VTRSViatris Inc. Common Stock	B	C	B	$16.72
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$260.23
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$252.99
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$80.40
CORTCorcept Therapeutics Inc.	F	C	A	$123.57
BMRNBioMarin Pharmaceuticals Inc	C	C	C	$66.12
ARWRArrowhead Research Corporation	D	A	B	$88.88
ELANElanco Animal Health Incorporated Common Stock	C	B	B	$25.09
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	$512.16
CYTKCytokinetics Inc.	F	D	B	$77.46
AXSMAxsome Therapeutics, Inc	D	B	C	$205.48
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.36
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$63.57
ABVXAbivax SA American Depositary Shares	—	—	C	$117.93
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.34
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$368.02
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PTGXProtagonist Therapeutics, Inc	F	B	A	$150.59
SYRESpyre Therapeutics, Inc. Common Stock	—	—	A	$107.36
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.86
TGTXTG Therapeutics, Inc.	D	B	A	$55.42
ALKSAlkermes Inc. plc	D	C	B	$49.21
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$113.35
ORKAOruka Therapeutics, Inc. Common Stock	F	—	A	$101.82
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	$161.68
COGTCogent Biosciences, Inc. Common Stock	F	—	B	$36.80

About Theriva Biologics, Inc.

Theriva Biologics is a clinical-stage biopharmaceutical company developing oncolytic adenovirus therapies for cancers with significant unmet medical needs. Its lead program, VCN-01, breaks down tumor stroma to enhance viral penetration, while preclinical program VCN-11 employs proprietary Albumin Shield Technology to protect oncolytic viruses from immune system inactivation during systemic delivery.